Company Overview of Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. The company’s RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. Its RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 20...
1880 Century Park East
Los Angeles, CA 90067
Founded in 2004
Key Executives for Ritter Pharmaceuticals, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $348.7K
Co-Founder, President and Director
Total Annual Compensation: $383.3K
Co-Founder, Executive Chairman and Chief Strategic Officer
Total Annual Compensation: $353.2K
Compensation as of Fiscal Year 2015.
Ritter Pharmaceuticals, Inc. Key Developments
Ritter Pharmaceuticals, Inc. Completes Patient Enrollment for its Phase 2B/3 Clinical Trial of its Investigational Compound RP-G28 for the Treatment of Lactose Intolerance
Aug 15 16
Ritter Pharmaceuticals, Inc. announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017. The Phase 2b/3 trial is a double-blind, placebo-controlled, three arm, multicenter study evaluating safety, efficacy and tolerability of two dosing regimens of its investigational compound RP-G28 in patients with moderate to severe lactose intolerance symptoms. Enrollment was initiated in March of 2016 and completed within 6-months, achieving the company's projected enrollment milestones. The study aims to evaluate a patient's ability to consume dairy foods post-treatment with improved tolerance and reduced digestive symptoms. A total of 377 subjects were enrolled in the trial with 18 clinical sites participating throughout the United States. Patients undergo a 30-day treatment, followed by a 30-day post-treatment evaluation of dairy tolerance. In addition, the study will evaluate each participant's microbiome, expanding knowledge of the effects that RP-G28 may have on adapting the gut microbiota in a beneficial manner.
Ritter Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
Aug 8 16
Ritter Pharmaceuticals, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2016. For the second quarter 2016, the company reported a net loss attributable to common stockholders of approximately $4,139,472 compared to $2,307,481 for the second quarter of 2015. Basic and diluted net loss per share was $0.48 for the three months ended June 30, 2016 compared to basic and diluted net loss per share of $4.18 for the same period in 2015. Operating loss was $4,156,133 against $2,099,831 a year ago.
For the six months, the company reported a net loss attributable to common stockholders of approximately $7,267,922 compared to $3,875,586 for the same period a year ago. Basic and diluted net loss per share was $0.85, compared to basic and diluted net loss per share of $7.62 for the same period in 2015. Operating loss was $7,306,363 against $3,496,130 a year ago.
Ritter Pharmaceuticals, Inc. Announces Earnings Results for the First Quarter 2016
May 9 16
Ritter Pharmaceuticals, Inc. announced earnings results for the first quarter 2016. For the first quarter of 2016, the company reported a net loss attributable to common stockholders of approximately $3.1 million compared to a net loss of approximately $1.6 million for the first quarter of 2015. Basic and diluted net loss per share was $0.36 for the first quarter of 2016 compared to basic and diluted net loss per share of $3.37 for the first quarter of 2015. Research and development expenses totaled approximately $1.9 million for the first quarter of 2016 versus approximately $31,000 for first quarter of 2015. This increase was driven by the preparation of adaptive design Phase 2b/3 clinical trial, which was initiated in March 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 18, 2015